Welcome to our dedicated page for IceCure Medical Ltd. SEC filings (Ticker: ICCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IceCure Medical Ltd. filings document the company’s status as a foreign private issuer and its disclosures around ProSense cryoablation technology, clinical and regulatory updates, commercial activity, governance and capital structure. Form 6-K reports furnish press releases on financial and operating results, FDA-related matters, medical-conference updates and clinical data for ProSense in tumor-destruction applications.
The filing record also includes proxy materials for shareholder voting, registration-statement references on Forms F-3 and S-8, ordinary-share voting information, executive and board changes, employment and indemnification arrangements, and litigation disclosure related to a prior private placement. These filings frame ICCM’s formal reporting around its medical-device business and public-company obligations.
IceCure Medical Ltd. amended its existing equity distribution agreement with Maxim Group LLC, which allows the company to offer and sell from time to time up to $13,960,500 of its ordinary shares through the sales agent. The amendment extends the agreement’s termination date from January 13, 2026 to March 13, 2026, keeping the at-the-market share sale program in place for two additional months.
The report states that this amendment is incorporated by reference into several of IceCure’s shelf and employee benefit registration statements, so any sales under the extended program would be made under those existing SEC registrations.
IceCure Medical Ltd. convened a Special General Meeting of Shareholders on January 7, 2026, where a quorum was present and shareholders approved all agenda items described in the previously distributed proxy statement.
As a result, amended and restated Articles of Association became effective immediately after the vote. The Articles formalize IceCure as a public company, define its share capital framework, and set rules for general meetings, including a quorum of at least two shareholders representing 25% of voting rights and the ability to vote by proxy or proxy statement.
The governance provisions include a staggered board structure where directors are generally appointed at Annual General Meetings, removal of directors requires a 70% majority of votes represented, and the board may fill vacancies and assign directors to board classes. The board is also authorized to adopt protective measures such as a shareholder rights plan and has broad discretion over dividends, bonus share distributions, reserve funds, and officer indemnification, exemption and insurance, all subject to applicable law.
IceCure Medical Ltd. furnished a report stating it issued a press release titled “IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer.” The title indicates the company expects record fourth quarter sales in North America and directly links this to the recent FDA clearance of its ProSense cryoablation system for treating low-risk breast cancer.
The company is also incorporating most of this press release by reference into several existing Form F-3 and Form S-8 registration statements, so the same information becomes part of those offering documents from the date of this report.
IceCure Medical Ltd. reported that it issued a press release on December 5, 2025 titled “IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes.” This indicates the company has received a notice of patent allowance in China for technology related to cryogen flow control, which is intended to optimize patient cryoablation outcomes.
The press release, excluding its third paragraph, is incorporated by reference into IceCure’s existing Form F-3 and Form S-8 registration statements, meaning the disclosure becomes part of those securities offering documents from the date of this report.
IceCure Medical Ltd. (ICCM) submitted a Form 6-K to furnish a press release covering its financial and operational results for the nine months ended September 30, 2025. The press release, dated November 19, 2025 and titled “IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025,” is attached as Exhibit 99.1.
Most of this press release, excluding its third, fourth, and fifth paragraphs, is incorporated by reference into IceCure’s existing registration statements on Form F-3 and Form S-8. This means the disclosed information becomes part of those registration statements from the date of this 6-K submission, unless later filings replace it.
IceCure Medical Ltd. reported that it issued a press release announcing that its ProSense® cryoablation system received regulatory approval in Switzerland for use in treating breast, lung, liver, and kidney cancer. The press release, dated November 18, 2025, is furnished as an exhibit to this report. Most of the press release (excluding its second paragraph) is also incorporated by reference into IceCure’s existing shelf and employee equity compensation registration statements on Forms F-3 and S-8, making the Swiss approval disclosure part of those offering documents.
IceCure Medical Ltd. (ICCM) furnished a Form 6-K noting it issued a press release titled “IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification.” The press release is attached as Exhibit 99.1.
The submission states this report is incorporated by reference into the company’s existing registration statements on Form F-3 (Nos. 333-258660, 333-267272, 333-290046) and Form S-8 (Nos. 333-270982, 333-264578, 333-262620, 333-281587).
IceCure Medical Ltd. (ICCM) announced a management change. On November 5, 2025, the Board promoted Mr. Shay Levav, previously Vice President of Regulatory and Quality Assurance and Clinical Applications since September 2020, to Chief Operating Officer.
The company also furnished a press release on November 10, 2025, and incorporated it by reference into its existing Form F-3 and Form S-8 registration statements.
IceCure Medical (ICCM) furnished a Form 6-K announcing it issued a press release titled “IceCure’s Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival.”
The press release (Exhibit 99.1) is incorporated by reference into the Company’s Registration Statements on Form F-3 (Nos. 333-258660, 333-267272, 333-290046) and Form S-8 (Nos. 333-270982, 333-264578, 333-262620, 333-281587).
IceCure Medical reported an executive change, delivering a notice of termination to Vice President of Operations and Services Galit Malik, with her employment ending on January 15, 2026. The company stated the termination was not related to any disagreement regarding operations, policies, or practices.
The report is furnished on Form 6-K and is incorporated by reference into IceCure Medical’s existing Form F-3 and Form S-8 registration statements.